Distribution in the brain and possible neuroprotective effects of intranasally delivered multi-walled carbon nanotubes.
Journal
Nanoscale advances
ISSN: 2516-0230
Titre abrégé: Nanoscale Adv
Pays: England
ID NLM: 101738708
Informations de publication
Date de publication:
26 Jan 2021
26 Jan 2021
Historique:
received:
17
10
2020
accepted:
12
11
2020
entrez:
22
9
2022
pubmed:
12
11
2020
medline:
12
11
2020
Statut:
epublish
Résumé
Carbon nanotubes (CNTs) are currently under active investigation for their use in several biomedical applications, especially in neurological diseases and nervous system injury due to their electrochemical properties. Nowadays, no CNT-based therapeutic products for internal use appear to be close to the market, due to the still limited knowledge on their fate after delivery to living organisms and, in particular, on their toxicological profile. The purpose of the present work was to address the distribution in the brain parenchyma of two intranasally delivered MWCNTs (MWCNTs 1 and a-MWCNTs 2), different from each other, the first being non electroconductive while the second results in being electroconductive. After intranasal delivery, the presence of CNTs was investigated in several brain areas, discriminating the specific cell types involved in the CNT uptake. We also aimed to verify the neuroprotective potential of the two types of CNTs, delivering them in rats affected by early diabetic encephalopathy and analysing the modulation of nerve growth factor metabolism and the effects of CNTs on the neuronal and glial phenotypes. Our findings showed that both CNT types, when intranasally delivered, reached numerous brain areas and, in particular, the limbic area that plays a crucial role in the development and progression of major neurodegenerative diseases. Furthermore, we demonstrated that electroconductive MWCNTs were able to exert neuroprotective effects through the modulation of a key neurotrophic factor and probably the improvement of neurodegeneration-related gliosis.
Identifiants
pubmed: 36131737
doi: 10.1039/d0na00869a
pii: d0na00869a
pmc: PMC9418508
doi:
Types de publication
Journal Article
Langues
eng
Pagination
418-431Informations de copyright
This journal is © The Royal Society of Chemistry.
Déclaration de conflit d'intérêts
There are no conflicts to declare.
Références
Data Brief. 2014 Dec 31;2:52-5
pubmed: 26217706
Nanomedicine (Lond). 2012 Oct;7(10):1485-94
pubmed: 22712575
Nat Nanotechnol. 2016 Jul;11(7):613-20
pubmed: 26974957
Handb Exp Pharmacol. 2014;220:17-32
pubmed: 24668468
J Alzheimers Dis. 2013;33(3):767-73
pubmed: 23001708
Curr Neurol Neurosci Rep. 2013 Oct;13(10):385
pubmed: 23990356
Int J Pharm. 2009 Sep 8;379(1):146-57
pubmed: 19555750
Nano Lett. 2012 Apr 11;12(4):1831-8
pubmed: 22432413
Proc Natl Acad Sci U S A. 2011 Jul 5;108(27):10952-7
pubmed: 21690348
Brain Res. 1995 Sep 18;692(1-2):278-82
pubmed: 8548316
Front Neurosci. 2016 Jun 09;10:269
pubmed: 27375426
Brain Res. 2015 Oct 22;1624:455-468
pubmed: 26282349
Eur J Pharm Sci. 2000 Jul;11(1):1-18
pubmed: 10913748
Adv Healthc Mater. 2014 Mar;3(3):424-32
pubmed: 23950018
J Comp Neurol. 1999 May 31;408(2):283-98
pubmed: 10333275
J Nanosci Nanotechnol. 2002 Oct;2(5):481-4
pubmed: 12908283
Front Neural Circuits. 2015 Sep 18;9:49
pubmed: 26441548
Prog Neurobiol. 2017 Oct;157:29-48
pubmed: 28743465
Mol Psychiatry. 2019 Jan;24(1):67-87
pubmed: 29679070
J Neurosci. 2007 Jun 27;27(26):6931-6
pubmed: 17596441
Chemistry. 2015 Dec 14;21(51):18631-41
pubmed: 26564100
J Neural Eng. 2018 Feb;15(1):016018
pubmed: 29064377
Nat Nanotechnol. 2011 Feb;6(2):121-125
pubmed: 21278749
Nat Nanotechnol. 2009 Feb;4(2):126-33
pubmed: 19197316
J Am Chem Soc. 2006 Oct 4;128(39):12899-904
pubmed: 17002385
Adv Healthc Mater. 2013 Mar;2(3):433-41
pubmed: 23184580
Sci Adv. 2016 Jul 15;2(7):e1600087
pubmed: 27453939
J Neurosci. 2011 Sep 7;31(36):12945-53
pubmed: 21900573
Int J Nanomedicine. 2012;7:2751-65
pubmed: 22701320
Science. 1982 Mar 5;215(4537):1237-9
pubmed: 7058341
J Control Release. 2016 Feb 28;224:165-175
pubmed: 26774220
Nanomedicine (Lond). 2008 Apr;3(2):149-61
pubmed: 18373422
Nanomedicine. 2018 Oct;14(7):2521-2532
pubmed: 28552645
J Drug Target. 2002 Aug;10(5):379-86
pubmed: 12442808
J Mol Neurosci. 2010 Jan;40(1-2):230-5
pubmed: 19680822
AAPS J. 2015 Jul;17(4):780-7
pubmed: 25801717
Neurobiol Aging. 2018 Sep;69:117-128
pubmed: 29890391
Drug Deliv. 2016;23(3):681-93
pubmed: 24901207
J Transl Med. 2012 Nov 29;10:239
pubmed: 23190582
Sci Rep. 2016 Aug 25;6:31732
pubmed: 27558973
Biomaterials. 2004 Mar-Apr;25(7-8):1309-17
pubmed: 14643605
Cells. 2019 Apr 01;8(4):
pubmed: 30939824
Front Cell Neurosci. 2014 Aug 07;8:220
pubmed: 25147503
Sci Rep. 2017 Aug 22;7(1):9077
pubmed: 28831054
Chemistry. 2011 Mar 21;17(13):3726-38
pubmed: 21394800
Nano Lett. 2004 Mar;4(3):507-511
pubmed: 21394241
Physiother Theory Pract. 2015;31(8):556-61
pubmed: 26492435
Adv Drug Deliv Rev. 2013 Dec;65(15):1964-2015
pubmed: 23954402
Nanomedicine. 2009 Mar;5(1):96-104
pubmed: 18693142
Basic Clin Pharmacol Toxicol. 2017 Sep;121 Suppl 3:30-43
pubmed: 27865054
J Pharm Sci. 2010 Apr;99(4):1654-73
pubmed: 19877171
Chem Rev. 2015 Oct 14;115(19):10816-906
pubmed: 25997028
Brain Inj. 2017;31(11):1538-1547
pubmed: 28972396
Nanomedicine. 2012 Apr;8(3):299-307
pubmed: 21723243
J Mol Neurosci. 2000 Jun;14(3):175-82
pubmed: 10984193
Neural Regen Res. 2014 May 15;9(10):1025-30
pubmed: 25206755
Neuroreport. 1993 Dec 13;5(3):273-6
pubmed: 8298089
Schizophr Res. 2017 Mar;181:2-3
pubmed: 28179064
Schizophr Res. 2015 Sep;167(1-3):1-3
pubmed: 26255083
J Nanobiotechnology. 2015 Dec 18;13:92
pubmed: 26683698
Nano Lett. 2005 Jun;5(6):1107-10
pubmed: 15943451
ACS Med Chem Lett. 2012 Dec 11;4(2):147-9
pubmed: 24900637
Curr Top Microbiol Immunol. 1990;156:27-54
pubmed: 2143132
Hippocampus. 2019 Oct;29(10):891-904
pubmed: 30870587